» Articles » PMID: 39202292

COVID-19-Related Cholangiopathy: Histological Findings

Overview
Specialty Radiology
Date 2024 Aug 29
PMID 39202292
Authors
Affiliations
Soon will be listed here.
Abstract

Methods: We subjected post-COVID-19 cholestasis liver samples to routine staining techniques and cytokeratin 7 immunostaining and semi-quantitatively analyzed the portal and parenchymal changes.

Results: All ten patients, five men, had a median age of 56, an interquartile range (IQR) of 51-60, and required intensive care unit and mechanical ventilation. The median and IQR liver enzyme concentrations proximal to biopsy were in IU/L: ALP 645 (390-1256); GGT 925 (664-2169); ALT 100 (86-113); AST 87 (68-106); and bilirubin 4 (1-9) mg/dL. Imaging revealed intrahepatic bile duct anomalies and biliary casts. We performed biopsies at a median of 203 (150-249) days after molecular confirmation of infection. We found portal and periportal fibrosis, moderate-to-severe ductular proliferation, and bile duct dystrophy in all patients, while we observed hepatocyte biliary metaplasia in all tested cases. We observed mild-to-severe parenchymal cholestasis and bile plugs in nine and six cases. We also observed mild swelling of the arteriolar endothelial cells in five patients. We observed a thrombus in a small portal vein branch and mild periductal fibrosis in one case each. One patient developed multiple small biliary infarctions. We did not observe ductopenia in any patient.

Conclusions: The alterations were like those observed in SSC-CIP; however, pronounced swelling of endothelial cells, necrosis of the vessel walls, and thrombosis in small vessels were notable.

References
1.
Cotter S, Wong J, Gada N, Gill R, Jones S, Chai G . Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series. Drug Saf. 2021; 44(12):1365-1374. PMC: 8546385. DOI: 10.1007/s40264-021-01120-9. View

2.
Santana M, Guerra M, Hundt M, Ciarleglio M, Pinto R, Dutra B . Correlation Between Clinical and Pathological Findings of Liver Injury in 27 Patients With Lethal COVID-19 Infections in Brazil. Hepatol Commun. 2021; 6(2):270-280. PMC: 8652714. DOI: 10.1002/hep4.1820. View

3.
Machado M, Kalil Filho R, El Bacha I, de Oliveira I, Ribeiro C, de Souza H . Post-COVID-19 Secondary Sclerosing Cholangitis: A Rare but Severe Condition with no Treatment Besides Liver Transplantation. Am J Case Rep. 2022; 23:e936250. PMC: 9394546. DOI: 10.12659/AJCR.936250. View

4.
Ghafoor S, Germann M, Jungst C, Mullhaupt B, Reiner C, Stocker D . Imaging features of COVID-19-associated secondary sclerosing cholangitis on magnetic resonance cholangiopancreatography: a retrospective analysis. Insights Imaging. 2022; 13(1):128. PMC: 9358102. DOI: 10.1186/s13244-022-01266-9. View

5.
Gudnason H, Bjornsson E . Secondary sclerosing cholangitis in critically ill patients: current perspectives. Clin Exp Gastroenterol. 2017; 10:105-111. PMC: 5491618. DOI: 10.2147/CEG.S115518. View